---
schema_version: "secwatch.filing_event.v1"
accession: "0001531048-24-000034"
form_type: "8-K"
ticker: null
cik: "0001531048"
company_name: "Inari Medical, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:21:25.686834+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inari Medical Q1 revenue $143.2M (+23% YoY); raises FY2024 guidance, GAAP net loss widens to $24.2M

## Summary
- Revenue $143.2M, up 23.3% YoY; gross margin 86.8% (down from 88.2% prior year).
- GAAP operating loss $17.2M vs $5.3M loss in Q1 2023; net loss $24.2M ($0.42 loss per share).
- Non-GAAP operating loss $5.6M, excluding $6.3M contingent consideration, $2.8M acquisition costs, $2.5M amortization.
- Raises FY2024 revenue guidance to $592.5M-$602.5M (from $580M-$595M); expects sustained profitability in H1 2025.
- PEERLESS study on track for H2 2024; growth driven by commercial expansion and new products.

## SEC filing metadata
- accession: 0001531048-24-000034
- form_type: 8-K
- cik: 0001531048
- company_name: Inari Medical, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/0001531048-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/nari-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001531048-24-000034
- JSON: https://secwatch.observer/filing/0001531048-24-000034.json
- Plain text: https://secwatch.observer/filing/0001531048-24-000034.txt

## Key facts
- Earnings Releases
  Inari Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $143.2 million, net income Net loss was $24.2 million, EPS net loss per share was $0.42. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $143.2 million
  - Net income: Net loss was $24.2 million
  - EPS: net loss per share was $0.42
  - Guidance: raised
  - Result: reported results
  source text: and other diseases, today reported financial results for its first quarter ended March 31, 2024. First Quarter Financial and Recent Business Highlights • Generated revenue of $143.2 million in Q1 of 2024, up 23.3% over the same quarter last year. • GAAP operating loss was $17.2 million in Q1 of 2024, compared to a $5.3 million operating loss in the same quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/0001531048-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.